Testicular seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Schmoll, H J ^a   Jordan, K ^a   Huddart, R ^b   Pes, M P Laguna ^c   Horwich, A ^b   Fizazi, K ^d   Kataja, V ^e  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; PACLITAXEL; ALPHA FETOPROTEIN; ANTIBIOTIC AGENT; CHORIONIC GONADOTROPIN; GRANULOCYTE COLONY STIMULATING FACTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; SEROTONIN 3 ANTAGONIST; STEROID; VINBLASTINE; VINDESINE;

ARTICLE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PRACTICE; DIAGNOSTIC VALUE; DRUG RESPONSE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MULTIPLE CYCLE TREATMENT; ORCHIECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SALVAGE THERAPY; SEMINOMA; TESTIS BIOPSY; ADJUVANT THERAPY; ADVANCED CANCER; CANCER CLASSIFICATION; CANCER RELAPSE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; ECHOGRAPHY; FIBROSIS; HIGH RISK PATIENT; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGONADISM; METABOLIC SYNDROME X; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OTOTOXICITY; PATIENT MONITORING; PNEUMONIA; POSTOPERATIVE CARE; PROGNOSIS; RAYNAUD PHENOMENON; SENSITIVITY AND SPECIFICITY; SURGICAL TECHNIQUE; TERATOMA; TESTIS NONSEMINOMA CANCER; TREATMENT RESPONSE; UROLOGIC SURGERY; YOLK SAC TUMOR;

ALPHA-FETOPROTEINS; CARCINOMA IN SITU; CHEMOTHERAPY, ADJUVANT; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; EUROPE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; L-LACTATE DEHYDROGENASE; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; ORCHIECTOMY; RECURRENCE; RISK ASSESSMENT; SALVAGE THERAPY; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 77954345456     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq176     Document Type: Article

References (16)

1. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
2. Oliver RT, Mason MD, Mead GM et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005; 366: 293-300.
3. Jones WG, Fossa SD, Mead GM et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005; 23: 1200-1208.
4. Horwich A, Oliver RT, Wilkinson PM et al. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. Br J Cancer 2000; 83: 1623-1629.
5. De Santis M, Becherer A, Bokemeyer C et al. 2-18Fluoro-deoxy-d-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22: 1034-1039.
6. Basu S, Rubello D. PET imaging in the management of tumors of testis and ovary: current thinking and future directions. Minerva Endocrinol 2008; 33: 229-256.
7. Schmoll HJ, Souchon R, Krege S et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15: 1377-1399.
8. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part I. Eur Urol 2008; 53: 478-496.
9. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2008; 53: 497-513.
10. van As NJ, Gilbert DC, Money-Kyrle J et al. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer 2008; 98: 1894-1902.
11. Huddart R, Kataja V. Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (Suppl 2): ii49-ii51.
12. Groll RJ, Warde P, Jewett MA. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol 2007; 64: 182-197.
13. de Wit R, Fizazi K. Controversies in the management of clinical stage I testis cancer. J Clin Oncol 2006; 24: 5482-5492.
14. Powles T, Robinson D, Shamash J et al. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 2008; 19: 443-447.
15. Oliver RT, Mead GM, Fogarty SP, Stenning SP. Radiotherapy versus carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214). J Clin Oncol 2008: 26 (Abstr 1).
16. Classen J, Schmidberger H, Meisner C et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 2003; 21: 1101-1106.